secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEKTAR THERAPEUTICS (NKTR)
CIK:        0000906709
Form:       8-K
Filed at:   2025-03-12T23:59:59+00:00
Accession:  0001213900-25-023220
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nektar Therapeutics reports Q4 net income $7.3M; rezpegaldesleukin Phase 2b data expected in 2025
--------------------------------------------------------------------------------

- Q4 net income $7.3M ($0.03 EPS) vs net loss $42.1M in Q4 2023; full year net loss $119M vs $276.1M.
- Revenue Q4 $29.2M (+22% YoY); cash $269.1M, expected to fund operations into Q4 2026.
- Rezpegaldesleukin Phase 2b topline data: atopic dermatitis in Q2 2025, alopecia areata in Q4 2025.
- FDA granted Fast Track designation for rezpegaldesleukin in moderate-to-severe atopic dermatitis.
- Sold PEGylation manufacturing business for $90M enterprise value ($70M cash + $20M equity).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/906709/000121390025023220/0001213900-25-023220-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/906709/000121390025023220/ea0234060-8k_nektar.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-023220

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer